Search

for
Search:

Research

5 / 1000+ results

Efficacy, Safety, and Dose Response of STS01, a Topical Controlled Release Nanoparticle Formulation (Dithranol/Prosilic), in Adults with Mild to Moderate Patchy Alopecia Areata: A Randomized, Double-Blind, Multicenter, Phase 2 Trial

research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial

April 2026 in “medRxiv”

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

research 62823 Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial

4 citations , September 2025 in “Journal of the American Academy of Dermatology”

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

March 2026 in “British Journal of Dermatology”

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

Health-Related Quality of Life in Mild-Moderate Patchy Alopecia Areata: Results from the First Controlled Phase 2 Clinical Trial with STS01 (Dithranol/ProSilic) and Future Challenges

research Health-related quality of life in mild-moderate patchy alopecia areata: Results from the first controlled Phase 2 clinical trial in this population with STS01 (dithranol/ProSilic) and challenges for the future

April 2026 in “medRxiv”

In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.

research Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo

January 2026 in “Journal of Investigative Dermatology”

This study found that 3D imaging may serve as a promising tool for objectively evaluating facial vitiligo repigmentation after treatment with upadacitinib.

View more "phase 2 trials" in research →

Community Join

5 / 1000+ results

community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed

24 upvotes 2 years ago

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

community People are hyped about PP405 but what about Veradermics phase 2!

in Research/Science 39 upvotes 11 months ago

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

community Pelage Recruiting Now for Phase 2

11 upvotes 2 years ago

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

community GT20029 Big Phase 2 Update Results!

53 upvotes 9 months ago

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

community It's the year 2050 and we are still waiting for Pelage to release the full phase 2 results of PP405 and start phase 3.

34 upvotes 7 months ago

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

View more "phase 2 trials" in community →

Learn

8 / 33 results

learn HMI-115

HMI-115: Frequently Asked Questions About Hair Loss Treatment HMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.

learn Bimatoprost

Can a lash-growth serum like bimatoprost actually work for your scalp? Bimatoprost (Latisse) is approved for eyelashes, not the scalp; two Allergan phase 2 trials in men with androgenetic alopecia posted results to ClinicalTrials.gov but were never published in a peer-reviewed journal, so scalp use remains off-label and experimental.

learn TDM-105795

How is TDM-105795 used in hair-related products, and is it being explored as a topical treatment, an oral option, or both? TDM-105795 is not sold in any hair product — it is an unapproved experimental compound. The public trial registry shows it has been studied only as a topical scalp solution, in three completed company trials (the largest a 71-participant, 16-week Phase 2); no oral programme is registered, and no peer-reviewed publication exists.

learn PP405

mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

Got small bald patches they say are from stress? PP405 sprays could help bring them back to life. PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier; its registered Phase 2 trial (NCT06393452) tested it once daily in 78 adults with pattern hair loss, for safety and tolerability. It is not approved, not for sale, and has not been studied in alopecia areata or stress-related shedding.
Did you know PP405 peptides can help protect your follicles from DHT? PP405 is not a peptide and does not block DHT: it is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, aimed at waking dormant follicles. Its registered Phase 2 trial (NCT06393452) measured safety and tolerability in 78 adults with pattern hair loss; it is not approved and not for sale.

learn Pyrilutamide

highly targeted anti-androgen that might have minimal systemic effects

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn Overview

learn Epidermal Growth Factor

View more "phase 2 trials" in learn →

Clinics

1 / 13 results

Hair Systems
Mane PhaseRancho Cucamonga, CA · US

Experts

— no results

Try a deeper search in experts →